1 2	Supporting Information for
2 3 4 5 6 7	SARS-CoV-2 in wastewater settled solids is associated with COVID-19 cases in a large urban sewershed
7 8 9 10 11 12	Katherine E. Graham ^{1*} , Stephanie K. Loeb ^{1*} , Marlene K. Wolfe ^{1*} , David Catoe ² , Nasa Sinnott- Armstrong ³ , Sooyeol Kim ¹ , Kevan M. Yamahara ⁴ , Lauren M. Sassoubre ⁵ , Lorelay M. Mendoza ¹ , Laura Roldan-Hernandez ¹ , Linlin Li ⁸ , Krista R. Wigginton ^{7#} , Alexandria B. Boehm ^{1#}
13 14	1. Department of Civil & Environmental Engineering, Stanford University, 473 Via Ortega, Stanford, CA, USA, 94305
15 16	2. Joint Initiative for Metrology in Biology, SLAC National Accelerator Laboratory, Stanford, CA,
17 18 19	 Department of Genetics, Stanford University School of Medicine, Stanford, CA Emmett Interdisciplinary Program in Environment and Resources, Stanford University, Stanford, CA
20 21 22 23	 Monterey Bay Aquarium Research Institute, Moss Landing, CA, USA, 95039, Department of Engineering, University of San Francisco, San Francisco, CA, USA, 94117 Department of Civil & Environmental Engineering, University of Michigan, Ann Arbor, MI, USA, 48109
24 25	8. County of Santa Clara Public Health Department, San Jose, California
26 27 28 29 30 31	* These authors contributed equally to this work. # Corresponding authors: Alexandria Boehm, 650-724-9128, <u>aboehm@stanford.edu</u> Krista Wigginton, (734) 763-2125, <u>kwigg@umich.edu</u>
32 33 34 35	Number of pages: 23 Number of Figures: 8 Number of Tables: 6

36 Materials and Methods

Sample collection. POTW A had thin sludge in their primary sedimentation tank that averaged about 900-1400 mg/L TSS when measured with a field probe. To obtain thicker sludge samples, operators collected 1000 mL of primary sludge at 8:00 each day, waited for the solids to settle (approximately 10 min), and decanted liquid to provide 40 mL of concentrated primary settled solids. The date assigned to a 24-hour composite sample is the date on which the majority of the sample was collected.

43 Storage conditions of samples. Method evaluation samples: For POTW A, influent samples 44 were stored at -20°C until analysis while solids samples were stored at -20°C for up to 3 days 45 and subsequently transferred to -80°C until analysis. Samples from POTW B were initially 46 stored at 4°C (median storage 9 d) and then transferred to storage at -20°C (influent) and -80°C 47 (solids) until analysis. Although immediate storage at -80°C is preferred, logistical constraints 48 and public health orders during the pandemic required initial refrigeration for samples from 49 POTW B. Longitudinal solids samples from POTW B were stored as described for the method 50 evaluation samples except median storage time at 4°C prior to being frozen was 4 days.

51

52 Influent PEG concentration and nucleic-acid extraction methods. Prior to beginning the PEG concentration procedure, 100 μ l of ~10⁷ cp/ml MHV strain A59 concentrate was spiked into 53 54 the clarified influent as a recovery standard. MHV is an enveloped beta coronavirus; it was 55 cultured, concentrated, and purified as described elsewhere^{1,2}. The MHV-spiked influent was 56 equilibrated on ice for 30 minutes. An aliquot was then immediately placed into a Qiagen 57 AllPrep PowerViral DNA/RNA extraction kit and nucleic acids were extracted and processed by 58 reverse-transcription quantitative polymerase chain reaction (RT-QPCR) for PMMoV and MHV 59 (methods below) to determine concentrations prior to the viral concentration procedure. 60 Subsequently, PEG8000 (MilliporeSigma, Burlington, MA) and NaCl were to the sample at final 61 concentrations of 8 g/100mL and 0.2 M, respectively. The sample was then shaken, and then 62 incubated overnight at 4°C. The following day, samples were centrifuged for 30 minutes at 63 20.000xg. 30 mL of the supernatant was discarded, and then the pellet was washed from the 64 side of the tube with the remaining supernatant and the samples were then centrifuged for 65 another 30 minutes at 20,000xg. The remaining supernatant was aspirated, and the virus-66 containing pellet was suspended in 200 µl of PBS and stored at -80°C until further processing 67 (within 3 days).

The concentrated influent was then thawed and spiked with 75 μ l of ~10⁷ copies/ml attenuated

69 bovine coronavirus (BCoV) vaccine (Calf-Guard, Zoetis) as an extraction positive control. The

70 attenuated BCoV was shipped lyophilized and resuspended in 3 mL of RNase/DNase-free water

and stored at 4°C. The resuspended BCoV stock was quantified by first extracting nucleic acids

from 0.2 mL with a Qiagen AllPrep PowerViral DNA/RNA kit and then quantifying with RT-

73 QPCR (methods below). Nucleic acids from concentrated influent samples were also extracted

vith the PowerViral DNA/RNA extraction kit following manufacturer's directions with two

- 75 modifications: 1) in step 8, 200 μl of solution IRS was added to samples to increase inhibitor
- removal, and 2) in step 16, water was added to the spin column, incubated for 5 minutes, and

77 then nucleic acids were eluted from the column. The final volume of the extract was 50 μ l. An

- 78 extraction blank (negative control) was included in each batch of sample extraction.
- 79

Additional details on solids processing. The exact mass of each aliquot of solids was
 recorded. Solids aliquoted for powerfecal extraction were then spiked with 5 µl of ~10⁷ copies/ml
 attenuated BCoV suspension, while solids aliquoted for RNeasy extraction were spiked with 20
 µl of the BCoV suspension. Samples were mixed and allowed to equilibrate on ice for 1 hour.
 Two biological replicates were completed per sample (2 powerfecal and 2 RNeasy extractions

- 85 per POTW per time point). To obtain RNA, nucleic acids were extracted according to the
- manufacturer protocol. The eluted volume of RNA from the two kits was 60 µl (powerfecal) and
 100 µl (RNeasy). Extraction blanks were run with each sample batch.
- 88

Reverse transcription prior to QPCR. The RNA was reverse transcribed to cDNA using iScript
cDNA synthesis kit (cat.no.: 1708890; Biorad, Hercules, CA) with random hexamers following
manufacturer's instructions. The 20 µL reactions consisted of 10 µL of RNA template, 4 µL of
iScript reaction mix, 1 µL of iScript reverse transcriptase mix, and 4µL of DNase/RNase-free
water. NTCs for the RT step consisted of the iScript RT master mix with 15 µL of RNAse/DNasefree water.

95 Generation of cDNA standards. cDNA standards for N1, N2, MHV and BCoV assays were 96 generated using TopTag Master Mix Kit for End-Point PCR following the recommended protocol 97 with 2 µL cDNA template and an annealing temperature gradient from 54-64°C. The template 98 for N1 and N2 consisted of plasmids from IDT containing sequences for the SARS-CoV-2 99 targets, the template for BCoV was a direct extraction of the vaccine strain, and the template for 100 MHV was a direct extraction from a concentrated solution of cultured MHV. PCR products were 101 identified using gel electrophoresis in 1X TAE for 40 mins at 100 V and bands were excised and 102 purified using a QIAquick Gel Extraction Kit. The mass of cDNA was then determined using a 103 Qubit fluorometer dsDNA kit. Standards were diluted into 30 x 30 µL aliguots at concentrations of 10⁶ cp/5 µL and stored at -80°C. Standards were thawed and diluted into the standard curve 104 105 concentrations immediately prior to use. PMMoV standards were DNA ultramers from IDT and were diluted in DNase/RNase-free water to a final concentration of 2.8 x 10⁶ gc/µl. NTCs in 106 107 duplicate were included on each plate.

108 QPCR assays. SARS-CoV-2 N1 and N2 qPCR assays were run in a 20 µL reaction using 109 TagPath gPCR Master Mix with 0.5 µM of each forward and reverse primer (IDT), 0.125 µM of 110 the probe (IDT), 5 µL cDNA template, and 0.625 mg/mL bovine serum albumin. Thermocycling 111 conditions consisted of a 2 min denature at 95°C, followed by 45 cycles of denaturing for 3 s at 112 95°C and annealing for 30 s at 55°C. BCoV assay was run in a 20 µL reaction using iTaq 113 Supermix, 0.5 µM of each forward and reverse primer, 0.125 µM of the probe, 0.625 mg/mL 114 BSA, and 5 µL cDNA template. Thermocycling conditions consisted of a 10 min denature at 115 95°C, followed by 45 cycles of denaturing for 15 s at 95°C, annealing for 30 s at 60°C and an 116 extension for 1 min at 60°C. MHV assay was run in a 20 µL reaction using TaqPath qPCR 117 Master Mix with 0.5 μ M of each forward and reverse primer, 0.125 μ M of the probe, 5 μ L cDNA 118 template, and 0.625 mg/mL bovine serum albumin. Thermocycling conditions consisted of a 2

- 119 min denature at 95°C, followed by 45 cycles of denaturing for 3 s at 95°C and annealing for 30 s
- 120 at 57°C. PMMoV assay was run in a 25 µL reaction using Environmental 2.0 Master Mix with
- 121 0.4 μM of each forward and reverse primer, 0.125 μM of the probe, and 2 μL cDNA template.
- 122 Thermocycling conditions consisted of a 10 min activation at 95°C, followed by 45 cycles of
- 123 denaturing for 15 s at 95° C and annealing for 1 min at 60° C.

124 ddRT-PCR assays. For method evaluation experiments, ddPCR SARS CoV-2 BioRad kit triplex

- assay was run according to the kit instructions using a 20 µL reaction with One-Step RT-ddPCR
- 126 Advanced Kit for Probes Supermix, 15 mM DTT, 1X primer/probe assay mix, and 5 μL RNA
- template. Final concentrations of the primers and probes were 900 nM and 250 nM,
- respectively. Thermocycling conditions consisted of 60 min RT at 50°C and 10 min enzyme
- activation at 95°C, followed by 40 cycles of 30 s denaturing at 94°C, and 30 s of annealing at
- 130 55° C, and a 10 min enzyme deactivation step at 98°C and 30 mins droplet stabilization at 4°C.
- 131 After stabilization, droplets were immediately transferred to the droplet reader, or stored
- 132 overnight at 4°C and enumerated using the plate reader the following day.
- 133 When transitioning from method optimization to running longitudinal samples for POTW B, we
- developed a duplex assay with only N1 and N2 targets (no human RNase P (RP) target). The
- duplex assay for N1 and N2 for the longitudinal samples was run according to the same
- parameters listed above. A duplex assay targeting BCoV and PMMoV was also developed to
- 137 calculate the recovery and fecal strength of each sample, respectively. For that assay, each well
- 138 was a 20 μL reaction with One-Step RT-ddPCR Advanced Kit for Probes Supermix, 15 mM
- DTT, 1X primer/probe assay mix, and 5 µL RNA template. Final concentrations of the primers
 and probes were 900 nM and 250 nM, respectively. Thermocycling conditions consisted of 60
- and probes were 900 nM and 250 nM, respectively. Thermocycling conditions consisted of 60
 min RT at 50°C and 10 min enzyme activation at 95°C, followed by 40 cycles of 30 s denaturing
- 142 at 94°C, and 30 s of annealing at 55°C, and a 10 min enzyme deactivation step at 98°C and 30
- 143 mins droplet stabilization at 4°C. After stabilization, droplets were immediately transferred to the
- 144 droplet reader, or stored overnight at 4°C and enumerated using the plate reader the following
- 145 day.

146 2-step ddRT-PCR. RT was performed as described above for QPCR using the iScript cDNA 147 synthesis kit from undiluted, 1:10 diluted, and 1:50 diluted RNA from solids samples. The 148 undiluted samples were also diluted 1:10 again before ddPCR to assess any difference in 149 inhibition. The generated cDNA was then used as template for a ddPCR simplex assay for the 150 SARS CoV-2 N1 target using the ddPCR supermix for probes with the same primer-probe 151 concentrations and thermocycling conditions specified in the BioRad SARS-CoV-2 Droplet 152 Digital PCR kit. Positive and negative controls were used as described above, and the same 153 criteria as described above were used for threshold setting, positive scoring, and minimum 154 droplet generation.

ddRT-PCR data analysis. During data analysis for method optimization experiments, clusters
 were assigned manually as described in the BioRad SARS-CoV-2 ddPCR Test Kit Instructions
 For Use. Samples were analyzed as duplicate merged wells, and the number of droplets
 generated exceeding 10,000 for all samples except one (7107 droplets), and with the average
 number of droplets generated being 15,000+. The fluorescence separation for the single

160 positive N1 cluster appeared above 1200 AU (Channel 1), separating from the negative cluster 161 by >6000 AU. The fluorescence separation for the single positive RP cluster appeared to the 162 right of 7000 AU (channel 2), separating from the negative cluster by >2000 AU. The single 163 positive N2 cluster was a 1:1 mix of channel 1 and 2 fluorophores, it appeared above 7000 AU 164 and overlapping or to the right of 5000 AU. Clusters containing dual positive targets were rare 165 outside of the positive control, but were assigned when present with separation from the single 166 clusters >500 AU. Representative example cluster data for an environmental sample, positive 167 control, and negative control, is shown in Figure S8. All NTCs were negative for SARS CoV-2 168 N1 and N2, although the occasional 1-2 positive RP droplets were identified in NTC samples. 169 Note that we did not use the RP results in our study. Three positive droplets per target were 170 required for a sample to be positive for that target. 171 172 173 For the longitudinal data which was generated using the duplex assays, we manually 174 thresholded the droplets in QuantaSoft Analysis Pro. Representative data from an 175 environmental sample, a positive control, and a negative control is shown in Figure S8. For 176 longitudinal data, the average number of accepted droplets was 37,666 (range: 15,913-59,813) for the N1/N2 duplex assay. The average copies per partition (lambda) was 2.6 x10⁻⁴ (range: 0-177 178 3.3x10⁻³). For the BCoV/PMMoV assay, the average number of accepted droplets was

179 29,911 (range: 14,345-45,333) and the average copies per partition was 0.0168 (range: 0-

180 0.986). Recovery of BCoV and PMMoV concentrations are shown in Figure S7. All NTCs and

181 extraction blanks were negative. Interplate variability was assessed by comparing

182 concentrations of the positive control wells on each plate.

183

184 See Table S6 for the reporting table from the dMIQE guidelines.

185

186

187

188

189

190

192 Table S1: Assay primers, probes, and conditions for all PCR assays.

193

Amplicon	Forward Primer	Reverse Primer	Starting Position	Ending Position	Size (# bases)	Probe Sequence	Probe Location
SARS CoV-2_N1	GAC CCC AAA ATC AGC GAA AT	TCT GGT TAC TGC CAG TTG AAT CTG	28287	28358	72	FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1	28309- 28332
SARS CoV-2_N2	TTA CAA ACA TTG GCC GCA AA	GCG CGA CAT TCC GAA GAA	29164	29230	67	FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1	29188- 29210
BCoV	CTGGAAG TTGGTGG AGTT	ATTATCG GCCTAA CATACAT C	29026	29110	85	CCTTCATA TCTATACA CATCAAGT TGTT	29058– 29085
PMMoV	GAGTGGT TTGACCTT AACGTTT GA	TTGTCG GTTGCA ATGCAA GT	1878	1945	68	FAM- CCTACCG AAGCAAAT G-MGB- NFQ	1906– 1921
МН∨	CACGCAG CTCGAAA GAAATG	GGATTA GATATC ATCCAC CTCTA	28690	28961	272	TAATGAAG AAATGAGA CTGCCCC TA	28913- 28937

194

196 Table S2. Summary of QPCR assay efficiencies and R² of standard curve regression. Ranges

197 are reported for all the plates ran for the project

Assay Target	Efficiency Range	R ² Range	
SARS CoV-2 N1	89.6 - 98.5	0.998 - 1	
SARS CoV-2 N2	88.1 - 96.2	0.996 - 1	
BCoV	81.3 - 96.0	0.996 - 0.997	
MHV	87.6 - 105.0	0.984 - 0.998	
PMMoV	77.8 - 96.3	0.990 - 0.999	

199 Table S3. RT-QPCR results for N1 and N2 SARS-CoV-2 targets. For influent, a "1" indicates a

200 positive including BLOQ and "0" a negative. For solids, the number of biological replicates with

201 at least one technical replicate positive is indicated (0, 1, or 2). The detected target is given in

202 parentheses adjacent to the number. A blank cell indicates that the particular sample type was

203 not run on that date.

Date	Influent POTW A (Palo Alto)	Solids POTW A (PowerFecal)	Influent POTW B (San Jose)	Solids POTW B (PowerFecal)	Solids POTW B (RNeasy)
3.22.20	0	0	0	1 (N1)	1 (N1)
3.23.20			0	1 (N1)	
3.25.20	0	0	1 (N2)	1 (N1)	1 (N1), 1 (N2)
3.29.20	0	0	0	0	2 (N1)
3.30.20			0	1 (N1)	
4.1.20	0	0	0	0	1 (N1)
4.15.20	0	1 (N1)	0	0	0

204 205

S8

- 207 Table S4. ddRT-PCR results for N1 and N2 SARS-CoV-2 targets. For influent, a "0" indicates
- 208 not detected, the concentration measured in copies/ml are provided for positive samples. For
- solids, the number of biological replicates positive is indicated (0, 1, or 2). The detected target is
- given in parentheses adjacent to the number. Solids concentrations are provided in Figure 1.

Date	Influent POTW A (Palo Alto)	A POTW A POTW B (San Jose)		Sludge POTW B (PowerFecal)	Sludge POTW B (RNeasy)
3.22.20	0	0	0	1 (N1) 2 (N2)	2 (N1, N2)
3.23.20			0	1 (N1, N2)	
3.25.20	10.9 (N1)	0	0	2 (N1, N2)	2 (N1, N2)
3.29.20	0	0	5.5 (N1)	2 (N1, N2)	2 (N1, N2)
3.30.20			0.5 (N2)	1 (N2)	
4.1.20	0	0	6.4 (N1)	2 (N1, N2)	2 (N1, N2)
4.15.20	0	0	5.8 (N1)	1 (N1) 2 (N2)	1 (N1, N2)

Table S5: Theoretical detection limits for N1 and N2 assays. Units are cp/g wet weight for solids and cp/ml for influent. Cells are blank if that dilution was not run.

2 step RT-qPCR 1 step RT-ddPCR 1 step RT-ddPCR Extraction Method (assuming 3 cp/ 2 (assuming 3 cp/ 3 (assuming 1 cp/ rxn) merged wells) merged wells) PowerFecal Undiluted 53 60 1:10 Dilution 530 600 1:50 Dilution 2700 Rneasy Undiluted 11 12 8 110 1:10 Dilution 120 80 1:50 Dilution 530 Influent - PowerViral Undiluted 0.5 0.4 1:10 dilution 5 4

216 217

219 Table S6: Average and standard deviations (SD) of Δ Cq for different dilutions of RNA for solids samples. Samples were extracted with either the Qiagen AllPrep PowerFecal RNA extraction kit 220 221 or the RNeasy PowerSoil RNA extraction kit. Samples were considered uninhibited if the ΔCq 222 for 1:10 dilutions were 2.3-4.3, as a 1:10 dilution with a 100% efficient assay would yield a ΔCq 223 of 3.3. Samples were considered uninhibited if the Δ Cq for 1:5 dilutions were 1.3-3.3, as a 1:5 224 dilution with a 100% efficient assay would yield a Δ Cq of 2.3. Whereas results from POTW A 225 suggest inhibition was alleviated by diluting 1:10, results indicate inhibition potentially remained 226 for POTW B.

		ΡΜΜοΥ ΔϹϥ		ΒCoV ΔCq	
		Average	SD	Average	SD
POTW A Power Fecal	1:10 - Undiluted	1.30*	0.65	2.85	0.68
	1:50 - 1:10	1.48	1.35	2.03*	0.91
POTW B Power Fecal	1:10 - Undiluted	-2.89*	1.15	0.73*	1.11
	1:50 - 1:10	-0.84*	0.89	-0.57*	0.88
POTW B RNeasy	1:10 - Undiluted	-1.87*	0.51	-0.44*	0.93
	1:50 - 1:10	-0.97*	0.76	-0.70*	1.02

227 *indicates sample types that showed inhibition, on average

228

229

- 231 Table S7: Details for essential and desired information as requested in the updated dMIQE
- guidelines³. Figure S8 provides example experimental results as suggested to report in section
 9 of the table.

ПЕМ ТО СНЕСК	PROVIDED	COMMENT	
	Y/N		
1. SPECIMEN			
Detailed description of specimen type and numbers	Y	included in methods section	
Sampling procedure (including time to storage)	Y	included in methods section	
Sample aliquotation, storage conditions and duration	Ť	Included in methods section	
2. NUCLEIC ACID EXTRACTION	× ×	induded in St	
Volume of column used to olute (resurpeed extract	T V	included in SI	
Number of extraction realizator	r V	included in SI	
Extraction blacks included?	v	included in methods section	
		neiddea in nethods section	
S. NOCLEIC ACID ASSESSMENT AND STORAGE Method to evaluate quality of pucleic acids	N	not done	
Method to evaluate quantity of nucleic acids (including molecular weight and calculations when using mass)	N	NA	
Storage conditions: temperature, concentration, duration, buffer, aliquots	Y	included in methods section and SI	
Clear description of dilution steps used to prepare working DNA solution	Y	included in methods section and SI	
4. NUCLEIC ACID MODIFICATION			
Template modification (digestion, sonication, pre-amplification, bisulphite etc.)	N	NA	
Details of repurification following modification if performed	Y	Zymo kit included in SI	
5. REVERSE TRANSCRIPTION			
cDNA priming method and concentration	Y	included in SI	
One or two step protocol (include reaction details for two step)	Y	included in methods section and SI	
Amount of RNA added per reaction	Y	included in SI	
Detailed reaction components and conditions	Y	included in SI	
Estimated copies measured with and without addition of RT*	N	not done	
Manufacturer of reagents used with catalogue and lot numbers	Y	inlcuded in SI	
Storage of cDNA: temperature, concentration, duration, buffer and aliquots	Y	included in methods section	
6. dPCR OLIGONUCLEOTIDES DESIGN AND TARGET INFORMATION			
Sequence accession number or official gene symbol	Y	included in SI	
Method (software) used for design and in silico verification	N	NA	
Location of amplicon	Y	in table S1	
Amplicon length	Y	in table S1	
Primer and probe sequences (or amplicon context sequence)**	Y	in table S1	
Location and identity of any modifications	N	NA	
Manufacturer of oligonucleotides	Y	included in SI	
7. APCR PROTOCOL			
Manufacturer of dPCR instrument and instrument model	Y	included in methods section	
Buffer/kit manufacturer with catalogue and lot number	Ŷ	included in methods section	
Primer and probe concentration	Y	inicuded in SI	
Pre-reaction volume and composition (incl. amount of template and if restriction enzyme added)	Y	included in SI	
Delementer (initial neating or chemical denaturation)	N	NA	
Complete thermourting parameters	N V	included in SI	
		included in Si	
Details of optimisation performed	Y	details of optimization performed in methods section and SI	
Analytical specificity (vs. related sequences) and limit of blank (LOB)	N	we did not perform an experiment to examine the LoB	
Analytical sensitivity/LoD and how this was evaluated	Y	included in methods section and SI- we determined a theoretically lowest concentration detected	
Testing for inhibitors (from biological matrix/extraction)	Y	included in methods section, in figures, and in SI	
9. DATA ANALYSIS			
Description of dPCR experimental design	Y	included in methods section and SI	
Comprehensive details negative and positive of controls (whether applied for QC or for estimation of error)	Y	included in methods and SI	
Partition classification method (thresholding)	Y	included in methods section	
Examples of positive and negative experimental results (including fluorescence plots in supplemental material)	Y	included in SI figures	
Description of technical replication	Y	included in methods section and SI	
Repeatability (intra-experiment variation)	Y	description of error included in methods section	
Reproducibility (inter-experiment/user/lab etc. variation)	Y	included in methods section and SI	
Number of partitions measured (average and standard deviation)	Y	included in SI	
Partition volume	N	did not estimate	
Lopies per partition (A or equivalent.) (average and standard deviation)	Y	included in SI	
device analysis program (source, version)	Y	included in methods section and SI	
Description or normalisation method Statistical methods used for applying	N	NA included in methods section and St	
Data transnarency	able on request:	raw data available upon request	
nara nanaharany	able on request:	raw data available upon request	

Table S8. Please see included excel file with results from statistical models.



240 Figure S1: Comparison of recovery of spiked SARS-CoV-2 RNA from PEG precipitation and 241 ultrafiltration methods to concentrate influent samples. Biological replicates of one sample were 242 concentrated using PEG precipitation and ultrafiltration, and SARS-CoV-2 RNA (from a high titer 243 clinical case) was spiked into nucleic acid extracts. Spiked extracts were then RTed as either 244 undiluted extracts or 1:10 dilutions in DNase/RNase-free water. The cDNA was then quantified 245 using gPCR: the 1:10 diluted extracts that were RTed were run as undiluted cDNA, and the 246 undiluted extracts that were RTed were run either undiluted or as 1:10 dilutions during qPCR. 247 Dilutions of the samples presented have already been accounted for by multiplying by the 248 dilution factor. Direct comparisons between PEG and ultrafiltration data revealed similar results 249 for both methods, and that diluting RNA before reverse transcription increased the recovery 250 more than diluting cDNA before qPCR, suggesting that inhibition in RT step affected recovery 251 more than inhibition in the qPCR step. Error bars represent standard deviations of technical 252 qPCR replicates (n=2). The influent sample tested here came from a wastewater treatment 253 plant located on Stanford Campus (Codiga Resource Recovery Center); this influent would 254 normally be delivered to POTW A.



Figure S2: Representative QPCR standard curves for each assay used during methodsoptimization experiments for influent and solids.



264

265 Figure S3. RT-QPCR results for endogenous (PMMoV) and exogenous (BCoV and MHV) 266 recovery targets at different dilutions to test for inhibition. Top row: PMMoV, BCoV, and MHV recoveries from influent at both POTW A and B with undiluted extracts, extracts diluted 1:10 267 prior to the RT step, and cDNA products diluted 1:10 prior to qPCR. Middle row: recoveries of 268 269 PMMoV and BCoV from solids collected at both POTW A and B and extracted with powerfecal 270 kit. Extracts were measured undiluted and diluted 1:10 and 1:50 prior to the RT step. Bottom 271 row: recoveries of PMMoV and BCoV from solids collected at POTW B with Rneasy kit. Extracts 272 were measured undiluted and diluted 1:10 and 1:50 prior to the RT step. The empty symbols 273 represent measurements below detection limits. Error bars represent standard deviation.



278 Figure S4: Mean concentrations of qPCR technical replicates of PMMoV in concentrated 279 influent samples (left y-axis); Mean recoveries of MHV and BCoV spike-in surrogates (using 280 gPCR technical replicates) (right y-axis). Measured by two-step RT-gPCR; MHV was spiked into 281 samples before concentrating and recovery was calculated by dividing concentrations in 282 concentrated influent by concentrations of unconcentrated influent (a subsample taken after the 283 MHV was spiked). BCoV was spiked into samples after concentration, but prior to nucleic acid 284 extraction and recovery was calculated by dividing by the theoretical concentration of BCoV 285 spiked into each sample, based on the concentration and volume of BCoV stock spiked. No 286 data available for POTW A for 3/23 and 3/30. Error bars on concentrations of MHV and PMMoV 287 represent the standard deviations of technical qPCR replicates (n=2). Due to constraints on the 288 availability of RNA template, the BCoV assay was not tested on samples diluted 1:10 before the 289 RT step.

290

291



296

297 Figure S5. N1, N2, PMMoV, and recovery of BCoV in solids from POTW B in each biological 298 replicate using data from the RNeasy kit. N1 and N2 data were obtained using digital RT-PCR in 299 the undiluted template unless the 1:10 diluted template produced a concentration higher than 300 the upper confidence bound on the undiluted template concentration; PMMoV and BCoV 301 recovery data were generated using RT-QPCR. The dilution of RT-QPCR template producing 302 the largest PMMoV concentration or BCoV recovery was used. Errors on RT-QPCR data are 303 standard deviations of technical replicates. Errors on ddRT-PCR data are total errors as 304 standard deviations. Each measurement is labeled with the POTW identifier (B) followed by the 305 date, followed by the biological replicate number (1 or 2). Error bars are not discernible from the 306 symbol in some cases.



308 Figure S6. N1, N2, PMMoV, and recovery of BCoV in solids from POTW A and B in each 309 biological replicate using data from the powerfecal kit. N1 and N2 data were obtained using 310 digital RT-PCR using undiluted template; PMMoV and BCoV recovery data were generated 311 using RT-QPCR. The dilution of RT-QPCR template producing the largest PMMoV 312 concentration or BCoV recovery was used. Errors on RT-QPCR data are standard deviations of 313 technical replicates. Errors on ddRT-PCR data are total errors as standard deviations. Each 314 measurement is labeled with the POTW identifier (A or B) followed by the date, followed by the 315 biological replicate number (1 or 2). Error bars are not discernible from the symbol in some 316 cases. 317



Figure S7. Recovery of BCoV and PMMoV concentrations for the longitudinal samples. Error bars represent the standard deviation as represented by the total error from the ddPCR

322 machine; they are difficult to see as they are often smaller than the symbol.



- 336 plots), a representative sample (middle facet plots), and a positive control containing SARS-
- 337 CoV-2 RNA isolated from clinical samples (N1 and N2- top two rows) or PCR standards (BCoV
- and PMMoV- bottom two rows) (right facet plots). The top two rows are 2D heat plots, with color

339 representing the density of droplets in each cluster, with red being a higher density and blue 340 representing a single droplet occupying that space. 2D heat plots were created with twoddPCR 341 ⁴. Negative droplets occur in the bottom left corner for all samples; there are many negative 342 droplets, resulting in the red cluster at Ch1 amplitude ~ 5000-7700, Ch2 amplitude ~ 2550-5000, in each plot for the triplex assay (top row) and cluster at Ch1 amplitude ~ 800-1400, Ch2 343 344 amplitude ~ 900-1250 in each plot for the duplex assay (middle row). Positive droplets are the 345 blue, green, and yellow clusters in the environmental sample and positive control plots (middle 346 and right panels) at Ch1 amplitude > 7700, Ch2 amplitude > 5000 for the triplex assay and Ch1 347 amplitude >1400, Ch2 amplitude > 1250 for the duplex assay. The bottom two rows are 1D plots 348 of results using the BCoV/PMMoV duplex assay. Colored droplets above the band of grey 349 negative droplets were considered positive droplets. 1D plots were exported from QuantaSoft 350 Analysis Pro (BioRad). All plates were manually thresholded in QuantaSoft Analysis Pro. NTCs 351 had at most 1-2 positive droplets for targets N1, N2, RP, BCoV, or PMMoV. 352

- 353
- 354

- 356 References
- 357 (1) Ye, Y.; Ellenberg, R. M.; Graham, K. E.; Wigginton, K. R. Survivability, Partitioning, and
 358 Recovery of Enveloped Viruses in Untreated Municipal Wastewater. *Environ. Sci. Technol.* 359 2016, *50* (10), 5077–5085. https://doi.org/10.1021/acs.est.6b00876.
- Rockey, N.; Arts, P. J.; Li, L.; Harrison, K. R.; Langenfeld, K.; Fitzsimmons, W. J.; Lauring,
 A. S.; Love, N. G.; Kaye, K. S.; Raskin, L.; Roberts, W. W.; Hegarty, B.; Wigginton, K. R.
 Humidity and Deposition Solution Play a Critical Role in Virus Inactivation by Heat
 Treatment on N95 Respirators. *medRxiv* 2020, 2020.06.22.20137448.
 https://doi.org/10.1101/2020.06.22.20137448.
- 365 (3) The dMIQE Group; Huggett, J. F. The Digital MIQE Guidelines Update: Minimum
 366 Information for Publication of Quantitative Digital PCR Experiments for 2020. *Clinical*
- 367 *Chemistry* **2020**, *66* (8), 1012–1029. https://doi.org/10.1093/clinchem/hvaa125.
- 368 (4) Chiu, A.; Ayub, M.; Dive, C.; Brady, G.; Miller, C. J. Twoddpcr: An R/Bioconductor Package
 and Shiny App for Droplet Digital PCR Analysis. *Bioinformatics* 2017, 33 (17), 2743–2745.
 370 https://doi.org/10.1093/bioinformatics/btx308.
- 371